Cassava Sciences, Inc. (SAVA), a pharmaceutical company specializing in Alzheimer's disease treatments, announced on Monday the appointment of Richard Barry as Chief Executive Officer.
On July 17, the Board appointed Barry as Executive Chairman and Principal Executive Officer, succeeding Remi Barbier, who stepped down from his CEO position.
Barry has been a director at Cassava since June 2021.
In line with the company's commitment to robust governance practices, the roles of CEO and Chairman have been bifurcated, with Claude Nicaise being appointed as Chairman.
Nicaise has been a director at Cassava since December 2023. His previous experience includes serving as Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014.
